Twist Bioscience and IMIDomics Join Forces for Immune-Mediated Inflammatory Disease Antibody Discovery
Twist Bioscience Corporation (NASDAQ: TWST) and IMIDomics, Inc. announced a new collaboration aimed at improving drug discovery and development for Immune-Mediated Inflammatory Diseases (IMIDs). Twist Bioscience, known for its high-quality synthetic DNA capabilities, will leverage its expertise in antigen development and its extensive Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.
IMIDomics, a patient-centric drug discovery and development company, will utilize its proprietary Clinical Discovery Engine™ to uncover the underlying mechanisms of IMIDs. Through multidimensional data analysis, this platform identifies targets previously unassociated with immune-mediated inflammatory diseases, opening up new possibilities for drug development. IMIDomics is currently focused on eight diseases, including Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn’s Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, and Sjögren’s Syndrome, aiming to develop innovative treatments for these conditions.
Under the terms of their collaboration, Twist Bioscience will receive upfront and project-specific fees, in addition to potential payments tied to clinical and commercial milestones, along with royalty payments based on product sales. In return, IMIDomics will gain access to human antibodies against several priority targets, fostering the advancement of their innovative drug development pipeline.
Emily M. Leproust, Ph.D., CEO, and co-founder of Twist Bioscience, expressed her enthusiasm for the partnership: “This collaboration with IMIDomics brings together expertise in relevant target identification and antibody discovery, two key areas needed for successful drug discovery and development. IMIDomics leverages its extensive biobank data to identify targets not previously associated with IMIDs. To discover antibodies that are highly specific to these targets, we will leverage the expertise of our Biopharma Solutions team across sites, utilizing our Twist Boston team for antigen production, which will be used by our team in South San Francisco to discover highly specific human antibody leads for IMIDomics.”